VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | CAR-T cell therapy DLBCL landscape

Ulrich Jäger • 12 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma Antibodies AUTO3 CAR-T Ibrutinib Pembrolizumab

Ulrich Jäger, MD, of the Medical University of Vienna, Vienna, Austria, discusses the current state of the art and future directions of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL) and novel data presented at EHA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ulrich Jäger

2:10
Should we treat high-risk DLBCL differently?
Ulrich Jäger • 12 Jun 2020
2:12
The regulation of personalized medicine trials
Ulrich Jäger • 15 Jun 2019
2:08
Updates on CAR T-cell therapy in B-cell malignancies
Ulrich Jäger • 9 Feb 2021
2:29
Bringing CAR T-cell therapy to the mainstream
Ulrich Jäger

Related Videos

0:34
First-line axicabtagene ciloleucel in lymphoma
Yago Nieto • 15 Feb 2021
1:44
Cord blood-derived NK cells with high-dose chemotherapy & ASCT for B-NHL
Yago Nieto • 15 Feb 2021
1:42
Infusion of CD30 CAR T-cells following AuHCT in patients with lymphoma
Marcie Riches • 15 Feb 2021
1:29
Future directions of immune cell therapy in lymphoma
Yago Nieto • 15 Feb 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals